Kenvue (NYSE:KVUE) Issues FY 2025 Earnings Guidance

Key Points

• Kenvue (NYSE:KVUE) has updated its FY 2025 earnings guidance, projecting an EPS of 1.000-1.050, which is below the consensus estimate of 1.136.
• The company has announced an increase in its quarterly dividend to $0.2075, representing a 3.9% annualized yield, with a dividend payout ratio of 149.09%.
• Analysts have recently lowered their price targets for Kenvue, with Barclays and Citigroup both setting targets of $22.00 and maintaining a "neutral" rating on the stock.

Kenvue (NYSE:KVUE - Get Free Report) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share guidance of 1.000-1.050 for the period, compared to the consensus earnings per share estimate of 1.136. The company issued revenue guidance of -.

Kenvue Price Performance

KVUE traded down $0.39 during trading on Friday, hitting $21.37. The company's stock had a trading volume of 25,925,024 shares, compared to its average volume of 21,613,902. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.63. Kenvue has a twelve month low of $19.75 and a twelve month high of $25.17. The business's fifty day simple moving average is $21.62 and its 200 day simple moving average is $22.40. The firm has a market capitalization of $41.00 billion, a price-to-earnings ratio of 28.88, a P/E/G ratio of 3.65 and a beta of 0.83.

Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.29 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.28 by $0.01. The firm had revenue of $3.84 billion for the quarter, compared to analyst estimates of $3.94 billion. Kenvue had a return on equity of 20.36% and a net margin of 9.37%. The business's revenue was down 4.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.32 earnings per share. On average, equities research analysts forecast that Kenvue will post 1.14 EPS for the current fiscal year.

Kenvue Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, August 27th. Stockholders of record on Wednesday, August 13th will be paid a $0.2075 dividend. This is a boost from Kenvue's previous quarterly dividend of $0.21. This represents a $0.83 dividend on an annualized basis and a dividend yield of 3.9%. The ex-dividend date of this dividend is Wednesday, August 13th. Kenvue's dividend payout ratio is presently 149.09%.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Redburn Atlantic assumed coverage on Kenvue in a research note on Thursday, April 10th. They issued a "neutral" rating and a $23.50 price target on the stock. JPMorgan Chase & Co. lowered their price target on Kenvue from $27.00 to $26.00 and set an "overweight" rating on the stock in a research note on Friday, July 25th. Citigroup lowered their price target on Kenvue from $24.50 to $22.00 and set a "neutral" rating on the stock in a research note on Tuesday, July 15th. Canaccord Genuity Group lowered their price target on Kenvue from $29.00 to $26.00 and set a "buy" rating on the stock in a research note on Friday. Finally, UBS Group lowered their price target on Kenvue from $25.00 to $23.00 and set a "neutral" rating on the stock in a research note on Thursday, July 17th. Seven analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $24.38.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.